Subsequently, many cytokines were used to enhance CAR T cell therapy, such as IL-7, IL-15, IL-18, IL-21, etc. Previous research of our group has shown that co-expression of IL-7 can enhance the anti-tumor effect of NKG2D-CAR T on prostate cancer (32). Here, IL21 is linked to prostate carcinoma.